LAIV DEVELOPMENT & PRODUCTION

Influenza vaccine strain selection, development, and production1,2

The influenza vaccine manufacturing process is complex and dependent on influenza strain recommendations from the WHO and the FDA1

  • Recommendations are based on an evaluation of surveillance data used to predict which influenza strains are likely to circulate in an upcoming season1
    • All year long, influenza centers across more than 100 countries monitor which influenza strains are making people sick, the extent those viruses are shedding, and how well the previous season’s vaccines protected against the targeted viruses1
    • The results of surveillance, laboratory, and clinical studies, and the availability of vaccine viruses, are reviewed twice yearly by the WHO1
    • Recommendations are made on the influenza vaccine composition for the Northern and Southern hemispheres in February and September, respectively
  • Following the WHO’s recommendations, it generally takes 6-8 months to produce large quantities of influenza vaccines1

FLUMIST QUADRIVALENT development and production requires additional time

  • FLUMIST QUADRIVALENT is a biologic product grown in eggs which needs to be developed, manufactured, and licensed each year3


Identification, production, and distribution of FLUMIST QUADRIVALENT takes approximately 6 months each year2

injection image

AstraZeneca is committed to helping you meet the flu vaccine needs of your patients. FLUMIST QUADRIVALENT is an important option for patients who may prefer an alternative to injections.4

WHO=World Health Organization, FDA=Food and Drug Administration.

IMPORTANT SAFETY INFORMATION


  • FLUMIST QUADRIVALENT is contraindicated in persons who have had a severe allergic reaction (eg, anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist
  • Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FLUMIST QUADRIVALENT administration. FLUMIST QUADRIVALENT has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • FLUMIST QUADRIVALENT has not been studied in immunocompromised persons
  • The safety of FLUMIST QUADRIVALENT in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine
  • FLUMIST QUADRIVALENT may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported were runny nose or nasal congestion in persons 2-49 years, fever >100°F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FLUMIST QUADRIVALENT, 32% reported runny nose or nasal congestion and 7% reported fever >100°F. Among adults 18-49 years who received FLUMIST QUADRIVALENT, 44% reported runny nose or nasal congestion and 19% reported sore throat

FLUMIST QUADRIVALENT is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUMIST QUADRIVALENT is for intranasal administration only.

Please see full Prescribing Information for FLUMIST QUADRIVALENT, including Patient Information.

You may report side effects related to AstraZeneca products by clicking here.